
Two zzso controlled trials of hormone therapy zzso were conducted within the US Women's Health zzso Both were chronic disease prevention trials, undertaken to determine whether zzso reduced cardiovascular risk and increased breast cancer zzso Because the majority of subjects in both trials were zzso and many years zzso and because substantial numbers had received zzso prior to recruitment to the trials, care must be taken in drawing conclusions that the observed risks are zzso to women for whom zzso is conventionally zzso Each of the reported risks must be examined critically to determine its likely zzso to symptomatic women treated for two to three years to relieve symptoms, but sometimes for substantially longer zzso Further, the risks reported in each of the two trials must be considered zzso zzso cardiovascular disease, many subjects in the trials were at increased baseline risk because of their age, body mass index, smoking status, blood pressure and years since menopause, in contrast to the usual situation for symptomatic zzso zzso Therefore the reported overall cardiovascular risks in zzso in both treatment arms, should be regarded as irrelevant to menopause zzso In contrast, breast cancer risk is relevant, providing that proper note is taken of the fact that there was no increased risk after five years of combined hormone therapy in zzso zzso users and there was a tendency to a decreased risk in zzso only treated zzso Other risks are zzso zzso 

